JP2017535567A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535567A5
JP2017535567A5 JP2017527366A JP2017527366A JP2017535567A5 JP 2017535567 A5 JP2017535567 A5 JP 2017535567A5 JP 2017527366 A JP2017527366 A JP 2017527366A JP 2017527366 A JP2017527366 A JP 2017527366A JP 2017535567 A5 JP2017535567 A5 JP 2017535567A5
Authority
JP
Japan
Prior art keywords
combination
alpha
desmopressin
adrenergic receptor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017527366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061686 external-priority patent/WO2016081772A1/en
Publication of JP2017535567A publication Critical patent/JP2017535567A/ja
Publication of JP2017535567A5 publication Critical patent/JP2017535567A5/ja
Pending legal-status Critical Current

Links

JP2017527366A 2014-11-20 2015-11-19 アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 Pending JP2017535567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082301P 2014-11-20 2014-11-20
US62/082,301 2014-11-20
PCT/US2015/061686 WO2016081772A1 (en) 2014-11-20 2015-11-19 Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020037385A Division JP2020097632A (ja) 2014-11-20 2020-03-05 アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物

Publications (2)

Publication Number Publication Date
JP2017535567A JP2017535567A (ja) 2017-11-30
JP2017535567A5 true JP2017535567A5 (enExample) 2018-12-27

Family

ID=54784026

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017527366A Pending JP2017535567A (ja) 2014-11-20 2015-11-19 アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2020037385A Withdrawn JP2020097632A (ja) 2014-11-20 2020-03-05 アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2022069213A Pending JP2022095948A (ja) 2014-11-20 2022-04-20 アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2024134846A Pending JP2024161452A (ja) 2014-11-20 2024-08-13 アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020037385A Withdrawn JP2020097632A (ja) 2014-11-20 2020-03-05 アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2022069213A Pending JP2022095948A (ja) 2014-11-20 2022-04-20 アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2024134846A Pending JP2024161452A (ja) 2014-11-20 2024-08-13 アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物

Country Status (11)

Country Link
US (1) US10286033B2 (enExample)
EP (1) EP3220942B1 (enExample)
JP (4) JP2017535567A (enExample)
KR (2) KR20170097045A (enExample)
CN (1) CN106999538A (enExample)
AU (1) AU2015349811B2 (enExample)
CA (1) CA2967390A1 (enExample)
DK (1) DK3220942T3 (enExample)
ES (1) ES2923438T3 (enExample)
MX (1) MX2017006655A (enExample)
WO (1) WO2016081772A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
EP4687859A2 (en) 2023-04-04 2026-02-11 Tulex Pharmaceuticals, Inc. Desmopressin oral compositions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
NZ241979A (en) 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
US6939324B2 (en) 2000-11-30 2005-09-06 Biovalve Technologies, Inc. Fluid delivery and measurement systems and methods
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
RU2321401C2 (ru) 2002-11-07 2008-04-10 Астеллас Фарма Инк. Лекарственное средство против гиперактивного мочевого пузыря, включающее производное анилида уксусной кислоты в качестве активного ингредиента
CA2866501A1 (en) * 2003-11-10 2005-05-26 Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
EP1968705A1 (en) 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
JPWO2007083640A1 (ja) 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
JP5185109B2 (ja) * 2006-04-21 2013-04-17 東興薬品工業株式会社 スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
KR20140143461A (ko) 2007-08-06 2014-12-16 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
CN101648017A (zh) * 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
US20110144055A1 (en) * 2008-09-04 2011-06-16 Rozmanith Anthony I Health Care
US20100160214A1 (en) 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
CA2747998C (en) 2008-12-22 2016-05-31 Allergan, Inc. Safe desmopressin administration
PT2442821T (pt) * 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
IN2012DN02782A (enExample) 2009-10-07 2015-09-18 Merck Sharp & Dohme
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
ES2634669T3 (es) * 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
CN107569690A (zh) * 2012-01-04 2018-01-12 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
MY174090A (en) * 2012-03-19 2020-03-09 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
MX2016001032A (es) * 2013-07-23 2017-10-31 Allergan Inc Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
CA2923270A1 (en) * 2013-09-03 2015-03-12 Shin Nippon Biomedical Laboratories Ltd. (Snbl) Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
JP2014177491A (ja) * 2014-06-26 2014-09-25 Allergan Inc 低用量デスモプレシンを含有する医薬組成物

Similar Documents

Publication Publication Date Title
Minkowitz et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain
Davies et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
Ripamonti Pain management
CN109640981A (zh) 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
ES2635733T3 (es) Uso de antagonistas opioideos para tratar la retención urinaria
ES2764167T3 (es) Película oral de dexametasona
Landwehr et al. A comparison between IV paracetamol and IV metamizol for postoperative analgesia after retinal surgery
JP2017506624A5 (enExample)
JP2020503269A5 (enExample)
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
MY205229A (en) Oral dosage form with drug composition, barrier layer and drug layer
JP2020500864A5 (enExample)
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
ES3062720T3 (en) Sublingual epinephrine tablets
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
JP2016505561A5 (enExample)
JP2016505050A5 (enExample)
JP2013510841A5 (enExample)
RU2012124038A (ru) Лекарственная комбинация с теобромином и ее использование в лечении
HRP20211488T1 (hr) Sastav i metoda za liječenje metaboličkih poremećaja
JP2019533672A5 (enExample)
MX2020002725A (es) Nueva formulacion de acido gamma-aminobutirico.